AIM ImmunoTech

Focus: AIM ImmunoTech is a biotechnology company headquartered in Ocala, Florida, focused on small molecules and biologics development. Limited publicly available data constrains assessment of market position and scale.

Oncology Infectious Diseases Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About AIM ImmunoTech

AI assessmentNot Hiring

No open roles listed right now. Follow AIM ImmunoTech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Poly I: Poly C12U

Chronic Fatigue Syndrome

N/A

Clinical Trials (1)

NCT00215813Ampligen in Chronic Fatigue Syndrome

N/A

Help build intelligence for AIM ImmunoTech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work across both small molecule and biologic modalities in an emerging biotech
Location in Ocala, FL may offer lower cost of living and reduced competition for talent versus major pharma hubs
Early-stage company structure could provide broader exposure to multiple therapeutic functions

Watch Out For

Zero active clinical trials and empty product pipeline suggest minimal near-term development momentum or revenue-generating catalysts
Absence of hiring activity (0 active job postings) indicates the company is not actively recruiting or may be in dormancy
Extremely limited public financial, staffing, and operational data raises transparency and stability concerns

Generated by Claude from AIM ImmunoTech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Biopsy

Triple -Negative Breast Cancer

Phase 1

Clinical Trials (1)

NCT03599453Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Phase 1

Cisplatin + celecoxib + DC vaccine

Cancer of Ovary

Phase 1/2

Clinical Trials (1)

NCT02432378Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Phase 1/2

Durvalumab

Metastatic Pancreatic Cancer

Phase 1/2

Clinical Trials (1)

NCT05927142Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

Phase 1/2

Recombinant Interferon Alfa-2b

Hematopoietic and Lymphoid Cell Neoplasm

Phase 1/2

Clinical Trials (1)

NCT04379518Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Phase 1/2

Rintatolimod

Ovarian Cancer Recurrent

Phase 1/2

Poly I:Poly C12U 50 ug

Influenza, Human